Planegg/Martinsried, February 3, 2025. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell ...
Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell engagers (TCR-TCEs), the “off-the-shelf” immunotherapies for solid ...
Medigene AG (Medigene, FSE: MDG1, Prime Standard) and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to ...
Hosted on MSN1mon
Medigene AG Advances with Equity Agreement to Boost CapitalMedigene ( (DE:MDG1)) has issued an update. Medigene AG has announced the execution of the first tranche of a Standby Equity Purchase Agreement with Yorkville Advisors Global, LP. This move will ...
Planegg/Martinsried, February 19, 2025.Medigene AG (Medigene, FSE: MDG1, Prime Standard) , an oncology platform company focused on the research and development of T cell receptor (TCR)-guided ...
Medigene AG, an oncology platform company focused on the research and development of T cell receptor (TCR)-guided therapies for the treatment of cancer, announced that the company has been issued a ...
Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided ...
The multi-target collaboration combines the respective expertise of each company with Medigene’s 3S (sensitive, specific and safe) TCR generation and characterization capabilities and EpimAb’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback